To view this email as a web page, click here.

Large Study Sheds Light on Risks for Second Cancers Among Young Survivors

Researchers investigated the risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer. Read more

Novel Genetic Marker in Ovarian, Lung Cancers

Two new studies found that targeting the cyclin-dependent kinases 4/6 exposed a vulnerability in SMARCA4-deficient cancers. Read more

IN CASE YOU MISSED IT

Aurora A Kinase Inhibitor vs Standard Treatment for PTCL

Is Aurora A kinase inhibitor alisertib superior to standard treatment protocol for peripheral T-cell lymphoma?

Read more

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.